

Our ref: FOI – 1507

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Information regarding treatment of breast cancer has now been considered and the information requested is enclosed.

ENC 1507

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) - <5
- Abemaciclib + Fulvestrant - <5
- Alpelisib + Fulvestrant - 0
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent – 0

Due to the level of specificity requested, provision of this information could identify individuals and therefore this information cannot be provided. The Trust has applied Section 40 (2) (third party information) of the Freedom of Information Act 2000 to exempt disclosure.

Part 2:

- Atezolizumab + Nab-paclitaxel/Paclitaxel - <5
- Capecitabine as a single agent - 6
- Eribulin as a single agent or in combination – 0

Due to the level of specificity requested, provision of this information could identify individuals and therefore this information cannot be provided. The Trust has applied Section 40 (2) (third party information) of the Freedom of Information Act 2000 to exempt disclosure.

- Everolimus + Exemestane – unable to answer from pharmacy data. Exemestane supplied through primary care therefore information not held on who receives this combination.
- Fulvestrant as a single agent – unable to answer from pharmacy data (not charged to patient) A manual trawl of patient records would be required. The cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It has been estimated that it would take more than 18 hours to locate and retrieve the requested information. In order to obtain this information, it would exceed the £450 fee limit and is therefore cost prohibitive.

- Lapatinib - 0
- Neratinib - 0
- Parp Inhibitors (Olaparib/Talazoparib) - <5
- Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) - 26
- Palbociclib + Fulvestrant - <5
- Pembrolizumab - none
- Platinum (e.g. carboplatin or cisplatin) as a single agent - <5
- Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) - 5
- Ribociclib + Fulvestrant - <5
- Sacituzumab Govitecan -<5

Due to the level of specificity requested, provision of this information could identify individuals and therefore this information cannot be provided. The Trust has applied Section 40 (2) (third party information) of the Freedom of Information Act 2000 to exempt disclosure.

Part 3:

- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 9
- Taxane and/or Anthracycline in combination - 43
- Trastuzumab as a single agent or in combination - 55 *
- Trastuzumab emtansine - 6
- Transtuzumab deruxtecan - <5
- Any other active systemic anti-cancer therapy
 - Abemaciclib & tamoxifen – <5
 - Vinorelbine (oral) – <5
 - *Tucatinib + capecitabine + Herceptin – <5 (included in trastuzumab data above)

Due to the level of specificity requested, provision of this information could identify individuals and therefore this information cannot be provided. The Trust has applied Section 40 (2) (third party information) of the Freedom of Information Act 2000 to exempt disclosure.

Q2. Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:

- early/locally advanced breast cancer (Stages 1 to 3B) - <5
- advanced/metastatic breast cancer (Stages 3C and 4) - <5

Due to the level of specificity requested, provision of this information could identify individuals and therefore this information cannot be provided. The Trust has applied Section 40 (2) (third party information) of the Freedom of Information Act 2000 to exempt disclosure.